API | acyline

acyline Report issue

Small molecule Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Acyline is a gonadotropin-releasing hormone analogue and gonadotropin-releasing hormone antagonist which was never marketed. It has been shown to suppress gonadotropin and testosterone levels in men. Acyline is a peptide and under normal circumstances is not orally active. For this reason, it has instead been administered by subcutaneous injection. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Gonadotropin-releasing hormone receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

acycline | acyline

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Androgens (Phase 1/Phase 2)

Contraception (Phase 1/Phase 2)

Contraceptive Agents, Male (Phase 2)

Deficiency Diseases (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1/Phase 2)

Healthy Volunteers (Phase 2/Phase 3)

Hypogonadism (Phase 1)

Insulin Resistance (Phase 1/Phase 2)

Metabolic Diseases (Phase 1/Phase 2)

Obesity (Phase 1/Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 16
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue